Chronic Obstructive Pulmonary Disease (COPD) is a wide term used for progressive lung diseases which includes chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. The symptoms of COPD includes recurrent coughing with or without sputum, difficulty in breathing, wheezing and tightness in the chest due to the blockage of lungs’ airways. More than 70 million people in the world are suffering from COPD as of 2015, majority of them being Americans.
For all the Chronic Obstructive Pulmonary Diseases, there is no cure but certain treatments help in improving quality of life of COPD patients. One of the effective treatments for COPD patients is COPD Inhalers. COPD inhalers can be further segmented into inhaler medicines and inhaler devices. Through inhaler devices, a medicine can be directly provided to the lungs, which is one of the most effective and quick treatment for COPD. This method of treatment also requires a smaller quantity of medicine as compared to that when one takes a medicine in tablets or liquid form.
The global market in terms of value for both inhaler devices and medicines is growing hand in hand as for the inhalation of medicines inhaling devices are required. According to the study conducted by MRFR analysts, the “Global COPD inhalers market is expected to reach ~$61.3 billion by 2022 with a compound annual growth rate of ~5.3% from 2016.”
COPD Inhalers Market: Segmentation & Analysis
Several types of COPD Inhaler devices are prevalent amongst COPD patients such as manually actuated pressurised metered-dose inhalers, breath-actuated pressurised metered-dose inhalers (MDIs), Dry Powder Inhalers (DPI) and mist inhalers. However, majority of COPD patients use actuated pressurised metered-dose inhalers (pMDIs) and Breath-actuated pressurised metered-dose inhalers which are small and handy inhalers which require pressurised inactive gas to impel a dose of medicine. Other types such as Dry powder inhalers and mist inhalers which are comparatively uses new technology are gaining the market attention and is showing higher pace of growth in this market.
Over the years, COPD inhaler medicines market has witnessed addition of innovative medicines for the treatment. Based on the severity of disease, Inhaler medicines are classified into rescue and controller medicines. Controller medicines are prescribed every day whereas rescue medicines are to be taken once in a while under the good control of COPD. Out of these two types, controller medicines command the major market share. These medicines are usually classified into short-acting bronchodilators (each dose effective for 3-6 hours), long- acting bronchodilators (each dose effective for at least 12 hours) and steroids (given in combination with a beta-agonist long-acting inhaler). Some of the established and highest revenue generating medicine brands in this segment are GSK’s Advair, AstraZeneca’s Symbicort, and Boehringer Ingelheim’s Spiriva.
COPD Inhalers Market: Regional Analysis
North America is recorded to be the largest and one of the rapidly growing markets due to increasing COPD cases. According to COPD foundation, there were around 30 million COPD people alone in America in 2015. The United States is one of the countries with highest number of COPD cases amongst other countries in North American region.
Following US Europe is the second-largest market in the world with the growing incidence of disease in the countries such as UK, France, Germany and Belgium. In Europe alone, about 55% of these total studies are conducted, UK being at the top of this list is conducting highest number of clinical trials along with Netherlands, Germany, Denmark, Belgium, Finland, Romania and other EU countries.
APAC followed by the Middle East and Africa are the growing markets in this industry due to increasing number of ageing population, a large number of COPD population, rising tobacco consumption and increased number of smoking population (COPD Foundation, 2017).
COPD Inhalers Market: Key Player Analysis
Some of the major players conducting these clinical trials comprises AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, GlaxoSmithKline, Novartis Pharmaceuticals, Teva pharmaceuticals, Merck &Co. and Chiesi Farmaceutici S.p.A. amongst others. GSK’s Triple combination therapy (fluticasone furoate/umeclidinium/vilanterol), mepolizumab 961081, 961081 + fluticasone furoate, 2269557 and danirixin; AstraZeneca’s PT010, PT003, benralizumab TERRANOVA GALATHEA, Teva Pharma’s TEV-48107 (tidal inhaler) are promising pipeline drugs in the COPD inhaler medicines market.
MRFR Analyst View:
Based on the current situations in the field of COPD therapeutic area, a good amount of research is going on by major pharmaceutical companies to find out the best possible treatment options for COPD. However, there is a dearth of focus on indirect treatment options such as COPD awareness campaigns and pulmonary rehabilitation canters. All the leading players in the industry can come up with such pulmonary rehabilitation centres as a part of their CSR activity which would help in the early detection of COPD. This initiative would also be useful for their branding and would clearly increase the treatment options for COPD patients giving them a better life.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312